Loading organizations...
Portola Capital Partners is an investment and advisory firm specializing in the global healthcare sector. The firm focuses on innovation, growth, and cross-border deals across North America, Asia, Europe, and emerging countries. It strategically leverages investments and advisory services to advance the healthcare landscape.
Information regarding the specific founding of Portola Capital Partners, including its founders' identities and the initial insights that led to its formation, is not publicly disclosed. The firm maintains a private stance on its historical development and the key individuals responsible for its establishment, operating discreetly within the investment community.
The firm targets companies developing innovative technologies and products that address significant unmet medical needs. Portola Capital Partners seeks opportunities capable of making a profound difference in patients' lives. Its vision centers on catalyzing advancements in the healthcare industry through strategic capital and guidance, aiming for widespread positive impact on patient outcomes.
Portola Capital Partners has 1 tracked investment across 1 company. The latest tracked deal is $80.0M Series C in Naurex in December 2014.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Dec 1, 2014 | Naurex | $80.0M Series C | — | ALSA Ventures, Soffinova Partners, Adams Street Partners, Baxter Ventures, Cowen Healthcare Investments, Druid BioVentures, Oleg Nodelman, Genesys Capital, Goudy Park Capital, H. Lundbeck, Latterell Venture Partners, Northwestern University, Sabby Capital, Savitr Capital, Takeda Ventures |